Meropenem in combination with baicalein exhibits synergism against extensively drug resistant and pan-drug-resistant Acinetobacter baumannii clinical isolates in vitro

Author:

Güran Mümtaz1ORCID,Çakıral Kadir12ORCID,Teralı Kerem3ORCID,Kandemir Tülay4ORCID,Şanlıtürk Gizem12ORCID,Öcal Melda Meral45ORCID,Nagiyev Toğrul4ORCID,Köksal Fatih4ORCID

Affiliation:

1. Department of Medical Microbiology, Faculty of Medicine, Eastern Mediterranean University , 99628 Famagusta, N. Cyprus via Mersin 10 , Turkey

2. Department of Chemistry, Faculty of Arts and Sciences, Eastern Mediterranean University , 99628 Famagusta, N. Cyprus via Mersin 10 , Turkey

3. Department of Medical Biochemistry, Faculty of Medicine, Cyprus International University , 99258 N. Cyprus via Mersin 10 , Turkey

4. Department of Medical Microbiology, Faculty of Medicine, Çukurova University , 1380 Adana , Turkey

5. Department of Biotechnology, Faculty of Science, The Campus of Çiftlikköy, Mersin University , 33343 Yenişehir, Mersin , Turkey

Abstract

Abstract Several studies have demonstrated that the effectiveness of carbapenems against drug-resistant Acinetobacter baumannii infections has been decreasing. Combination therapy with two or more drugs is currently under investigation to overcome the emerging resistance against carbapenems. In this study, we tested the possible synergistic interactions of a potent antibacterial flavonoid, baicalein, with meropenem to illustrate this duo’s antibacterial and antibiofilm effects on 15 extensively drug resistant or pan-drug-resistant (XDR/PDR) A. baumannii clinical isolates in vitro. Isolates included in the study were identified with MALDI-TOF MS, and antibiotic resistance patterns were studied according to EUCAST protocols. Carbapenem resistance was confirmed with the modified Hodge test, and resistance genes were also analyzed with genotypical methods. Then, checkerboard and time-kill assays were performed to analyze antibacterial synergism. Additionally, a biofilm inhibition assay was performed for screening the antibiofilm activity. To provide structural and mechanistic insights into baicalein action, protein–ligand docking, and interaction profiling calculations were conducted. Our study shed light on the remarkable potential of the baicalein–meropenem combination, since either synergistic or additive antibacterial activity was observed against every XDR/PDR A. baumannii strain in question. Furthermore, the baicalein–meropenem combination displayed significantly better antibiofilm activity in contrast to standalone use. In silico studies predicted that these positive effects arose from inhibition by baicalein of A. baumannii beta-lactamases and/or penicillin-binding proteins. Overall, our findings highlight the prospective potential benefits of baicalein in combination with meropenem for the treatment of carbapenem-resistant A. baumannii infections.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine,Immunology and Allergy

Reference44 articles.

1. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study;Assimakopoulos;Infez Med,2019

2. Meropenem;Baldwin;Drugs,2008

3. Protoss: a holistic approach to predict tautomers and protonation states in protein-ligand complexes;Bietz;J Cheminform,2014

4. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences;Burley;Nucleic Acids Res,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3